Evidence map›Paper›PMID 42008709›Full record

ArticleDiabetes care2026

Merging T1D and T2D Management: Shared Strategies for Common Goals-Building on Early Lessons From GLP-1 Trials in T1D.

Richard M Bergenstal, Holly J Willis, Anders L Carlson

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Richard M BergenstalInternational Diabetes Center, HealthPartners Institute, Minneapolis, MN.ORCID 0000-0002-9050-5584
Holly J WillisInternational Diabetes Center, HealthPartners Institute, Minneapolis, MN.
Anders L CarlsonInternational Diabetes Center, HealthPartners Institute, Minneapolis, MN.ORCID 0000-0002-5738-2818

Funding

Mitigating Diabetic Ketoacidosis in People with T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation into an Enhanced Glucose Ketone ReportU01DK143379 · HEALTHPARTNERS INSTITUTE · 2025 to 2025
$2.4M
NIDDK NIH HHS U01 DK143379Park Nicollet Foundation NA
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42008709
PMCPMC13094863

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.